Top

Strahlentherapie und Onkologie

Published in:

01-08-2016 | Original Article

Modulation of radiation-induced oral mucositis by thalidomide

Preclinical studies

Authors: Katharina Frings, Sylvia Gruber, Peter Kuess, Miriam Kleiter, Univ.-Prof. Dr. Wolfgang Dörr

Published in: Strahlentherapie und Onkologie | Issue 8/2016

Abstract

Purpose

Oral mucositis is a common, dose-limiting early side effect of radio(chemo)therapy for head-and-neck tumors. The epithelial radiation response is accompanied by changes in the inflammatory signaling cascades mediated by the transcription factor nuclear factor-kappa B (NF-κB). The present study was initiated to determine the effect of the NF-κB inhibitor thalidomide on the clinical manifestation of oral mucositis in the established mouse tongue model.

Materials and methods

Treatment protocols comprised single dose irradiation and daily fractionated irradiation (5 fractions of 3 Gy/week) over 1 (days 0–4) or 2 weeks (days 0–4, 7–11), alone or in combination with daily thalidomide application (100 mg/kg intraperitoneally) over varying time intervals. Fractionation protocols were terminated by graded local radiation doses (day 7/14) to generate full dose-effect curves. Tongue epithelial ulcerations, corresponding to confluent mucositis, served as the clinically relevant endpoint.

Results

Thalidomide application did not show a significant radioprotective potential when administered in combination with single dose irradiation. Thalidomide in combination with one week of fractionated irradiation significantly increased the isoeffective top-up doses. Similar results were observed during two weeks of fractionated irradiation in all but one experiment.

Conclusion

Thalidomide treatment demonstrated a significant mucositis-ameliorating effect during fractionated irradiation, which is likely to result from NF-κB inhibition. However, further mechanistic studies are required to define the underlying mechanisms of the observed mucoprotective effect.

Elting LS, Keefe DM, Sonis ST et al (2008) Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. Cancer 113:2704–2713CrossRefPubMed

Zur E (2012) Oral mucositis: etiology, and clinical and pharmaceutical management. Int J Pharm Compd 16:22–33PubMed

Russo G, Haddad R, Posner M, Machtay M (2008) Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist 13:886–898CrossRefPubMed

Bese NS, Hendry J, Jeremic B (2007) Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys 68:654–661CrossRefPubMed

Murphy BA (2007) Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol 5:13–21PubMed

Gruber S, Schmidt M, Bozsaky E et al (2014) Modulation of radiation-induced oral mucositis by pentoxifylline: preclinical studies. Strahlenther Onkol 191:242–247CrossRefPubMed

Albert M, Schmidt M, Cordes N, Dörr W (2012) Modulation of radiation-induced oral mucositis (mouse) by selective inhibition of ß1 integrin. Radiother Oncol 104:230–234CrossRefPubMed

Haagen J, Krohn H, Rollig S et al (2009) Effect of selective inhibitors of inflammation on oral mucositis: preclinical studies. Radiother Oncol 92:472–476CrossRefPubMed

Brizel DM, Murphy BA, Rosenthal DI et al (2010) Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 26:677–683

10.

Henke M, Alfonsi M, Foa P et al (2011) Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol 29:2815–2820CrossRefPubMed

11.

Viet CT, Corby PM, Akinwande A, Schmidt BL (2014) Review of preclinical studies on treatment of mucositis and associated pain. J Dent Res 93:868–875CrossRefPubMedPubMedCentral

12.

Sonis S (2004) A biological approach to mucositis. J Support Oncol 2:21–36PubMed

13.

Sonis ST (2007) Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 5:3–11PubMed

14.

Logan RM, Stringer AM, Bowen JM et al (2008) Serum levels of NF-κB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 777:1139–1145CrossRef

15.

Han G, Bian L, Li F et al (2013) Preventive and therapeutic effects of Smad7 on radiation- induced oral mucositis. Nat Med 19:421–428CrossRefPubMedPubMedCentral

16.

Lambros PM, Parsa C, Mulamalla H et al (2011) Identifying cell and molecular stress after radiation in a three-dimensional (3‑D) model of oral mucositis. Biochem Biophys Res Commun 405:102–106CrossRefPubMed

17.

Jurenka JS (2009) Anti-inflammatory properties of curcumin, a major constituent of curcuma longa: a review of preclinical and clinical research. Altern Med Rev 14:141–153PubMed

18.

Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS (2001) Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J Biol Chem 276:22382–22387CrossRefPubMed

19.

Franks ME, Macpherson GR, Figg WD (2004) Thalidomide. Lancet 363:1802–1811CrossRefPubMed

20.

Lima V, Brito GAC, Cunha FQ et al (2005) Effects of the tumour necrosis factor-α inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. Eur J Oral Sci 113:210–217CrossRefPubMed

21.

Fehrmann A, Dörr W (2005) Effect of EGFR-inhibition on the radiation response of oral mucosa: experimental studies in mouse tongue epithelium. Int J Radiat Biol 81:437–443CrossRefPubMed

22.

Dörr W, Heider K, Spekl K (2005) Reduction of oral mucositis by palifermin (rHuKGF): dose-effect of rHuKGF. Int J Radiat Biol 81:557–565CrossRefPubMed

23.

Schmidt M, Haagen J, Noak R et al (2014) Effects of bone marrow or mesenchymal stem cell transplantation on oral mucositis (mouse) induced by fractionated irradiation. Strahlenther Onkol 190:399–404CrossRefPubMed

24.

Ong ZY, Gibson RJ, Bowen JM et al (2010) Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol 5:1–8CrossRef

25.

Xanthinaki A, Nicolatou-Galitis O, Athanassiadou P et al (2008) Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. Support Care Cancer 16:1025–1033CrossRefPubMed

26.

Lalla R, Choquette L, Curley K (2014) Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol 50:1098–1103CrossRefPubMedPubMedCentral

27.

Payvandi F, Wu L, Haley M et al (2004) Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-α, IL-1β, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol 230:81–88CrossRefPubMed

28.

Jaal J et al (2010) Effect of recombinant human keratinocyte growth factor (∆23rHuKGF, palifermin) on inflammatory and immune changes in mouse tongue during fractionated irradiation. Int J Radiat Biol 86:860–876CrossRefPubMed

29.

Greenwood J, Amos CL, Walters CE et al (2003) Intracellular domain of brain endothelial intercellular adhesion molecule-1 is essential for T lymphocyte-mediated signaling and migration. J Immunol 171:2099–2108CrossRefPubMedPubMedCentral

30.

Chen C, Chou C, Sun Y, Huang W (2001) Tumor necrosis factor alpha-induced activation of downstream NF-kappaB site of the promoter mediates epithelial ICAM-1 expression and monocyte adhesion. Involvement of PKCalpha, tyrosine kinase, and IKK2, but not MAPKs, pathway. Cell Signal 13:543–553CrossRefPubMed

31.

Geitz H, Handt S, Zwingenberger K (1996) Thalidomide selectivity modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31:213–221CrossRefPubMed

32.

Lin YC, Shun CT, Wu MS, Chen CC (2006) A novel anticancer effect of thalidomide: Inhibition of intercellular adhesion molecule-1–mediated cell invasion and metastasis through suppression of nuclear factor-κB. Clin Cancer Res 12:7165–7173CrossRefPubMed

33.

Dörr W (2009) Pathogenesis of normal tissue side- effects. In: Joiner M, Kogel A van der (eds) Basic clinical radiobiology, 4th edn. Hodder Arnold, London, pp 169–190CrossRef

34.

Dörr W (2003) Modulation of repopulation processes in oral mucosa: experimental results. Int J Radiat Biol 79:531–537CrossRefPubMed

35.

Dörr W (1997) Three A’s of repopulation during fractionated irradiation of squamous epithelia: asymmetry loss, acceleration of stem-cell divisions and abortive divisions. Int J Radiat Biol 72:635–643CrossRefPubMed

Title: Modulation of radiation-induced oral mucositis by thalidomide
Preclinical studies
Authors: Katharina Frings
Sylvia Gruber
Peter Kuess
Miriam Kleiter
Univ.-Prof. Dr. Wolfgang Dörr
Publication date: 01-08-2016
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 8/2016
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-016-0989-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Modulation of radiation-induced oral mucositis by thalidomide

Preclinical studies

Abstract

Purpose

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2016

Restaging-PET-CT nach Radiochemotherapie kann Patienten mit fortgeschrittenen HNO-Karzinomen die elektive Neck-Dissektion ersparen, sofern sie eine komplette Remission zeigen

Keine generelle Empfehlung zum Verzicht auf eine konsolidierende Radiotherapie bei Morbus Hodgkin und PET-negativem Befund nach abgeschlossener Chemotherapie

Der Stellenwert der Operation bei der Behandlung des resektablen nicht-kleinzelligen Lungenkarzinoms im Stadium III

The field size matters: low dose external beam radiotherapy for thumb carpometacarpal osteoarthritis

Situation of young radiation oncologists, medical physicists and radiation biologists in German-speaking countries

IMRT/VMAT for malignancies in the head-and-neck region